Skip to main content
. 2023 Mar 14;14:1093442. doi: 10.3389/fphar.2023.1093442

TABLE 1.

Comparison of baseline data in different treatment groups for severe IgAN (n = 98).

Group P + CTX group P + MMF group P Group Supportive treatment group P
(n = 35) (n = 26) (n = 20) (n = 17)
men, n (%) 15 (42.90) 11 (42.30) 8 (40.00) 8 (47.10) 0.98
Year at biopsy (Y) 35.5 ± 9.2 39.3 ± 13.0 36.9 ± 12.4 43.2 ± 10.3 0.11
SBP (mmHg) 134.7 ± 19.1 134.4 ± 23.8 135.8 ± 34.1 134.6 ± 22.7 1.00
DBP (mmHg) 83.0 ± 14.2 80.8 ± 13.2 82.0 ± 15.7 81.4 ± 12.7 0.94
MAP (mmHg) 100.2 ± 15.1 98.7 ± 16.0 99.9 ± 20.3 99.1 ± 14.8 0.99
Hematuria, n (%), 25 (71.40) 19 (73.10) 15 (75.00) 9 (52.90) 0.44
HGB (g/L) 129.57 ± 21.38 126.25 ± 17.35 122.09 ± 21.70 129.06 ± 20.61 0.59
ALT (U/L) 13.60 (8.50–22.90) 14.70 (9.88–20.10) 16.25 (10.80–25.15) 18.00 (14.00–26.65) 0.41
CHO (mmol/L) 5.42 ± 1.32 5.54 ± 0.93 5.26 ± 1.32 5.58 ± 1.35 0.84
Cys C (mg/L) 0.91 (0.69–1.29) 0.95 (0.75–1.29) 0.99 (0.70–1.13) 1.13 (0.75–1.33) 0.62
SUA (μmol/L) 403.30 (358.60–488.50) 413.05 (352.95–523.25) 441.35 (360.00–555.67) 504.00 (426.90–552.50) 0.13
BUN (mmol/L) 5.00 (3.75–8.28) 6.21 (4.81–9.27) 6.40 (4.31–7.89) 8.60 (6.19–10.86) 0.12
ALB (g/L) 38.80 (34.00–42.40) 37.05 (34.63–42.15) 36.65 (33.20–41.33) 39.90 (35.10–43.70) 0.63
Scr (μmol/L) 94.00 (64.00–153.00) 100.00 (87.00–142.25) 97.00 (76.00–119.50) 136.00 (88.50–209.50) 0.17
PCR (g/g) 1.71 (0.85–3.02) 1.35 (0.83–2.00) 1.17 (0.63–2.71) 0.84 (0.45–2.88) 0.49
24-UPro (g/d) 1.49 (1.03–2.92) 1.79 (0.82–2.52) 1.25 (0.76–3.37) 1.14 (0.61–3.39) 0.47
eGFR (mL/min/1.73m2) 75.77 (43.11–116.19) 64.66 (38.27–86.68) 70.79 (60.13–98.29) 42.61 (27.46–80.82) 0.14
CKD staging (%) 0.24
1 16 (45.70) 6 (23.10) 5 (25.00) 3 (17.60)
2 6 (17.10) 9 (34.60) 9 (45.00) 3 (17.60)
3 8 (22.90) 6 (23.10) 4 (20.00) 6 (35.30)
4 5 (14.30) 5 (19.20) 2 (10.00) 5 (29.40)
*Lee’s grades, n (%) 31(88.60) 21(80.80) 17(85.00) 8(47.10) 0.01
M1, n (%) 19 (54.30) 15 (57.70) 13 (65.00) 5 (29.40) 0.16
*S1, n (%) 35 (100.00) 26 (100.00) 20 (100.00) 13 (76.50) 0.01
E1, n (%) 16 (45.70) 15 (57.70) 11 (55.00) 5 (29.40) 0.28
T (1 + 2), n (%) 28 (80.00) 23 (88.50) 17 (85.00) 16 (94.10) 0.63

*Comparison among four groups, p < 0.05.